Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
The Polish Development Fund (PFR) will hold the CEE Innovators Summit on 28 March 2017. Other special guests include Professor Mariana Mazzucato, the author of The Entrepreneurial State, along with other innovators and entrepreneurs. Startups, innovative NGOs in the V4, heads of company R&D departments, and representatives of public administration from the region are invited to attend the two-day meeting in Warsaw.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8064951-pfr-cee-innovators-summit-poland/
ADP®, a leading provider of human resources outsourcing, payroll services, benefits administration and integrated computing solutions for vehicle dealers, today introduced ADP Vantage HCMSM, the industry’s first complete employee lifecycle solution for large organizations. ADP Vantage HCM is the culmination of an 18-month research and development effort by ADP to create a unified, fully-integrated platform combining the pillars of human capital management: HR, payroll, benefits, talent management and time & attendance. The company unveiled the much anticipated system at the 14th Annual HR Technology® Conference in Las Vegas, Nevada today.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52456-adp-unveils-vantage-unified-cloud-based-system-human-capital-management
For negotiators at the Paris climate conference (COP21) to successfully advance global efforts to reduce carbon emissions, nations must embrace a prominent role for nuclear energy.
The Obama administration highlighted the crucial role of nuclear energy when it convened a White House Summit on Nuclear Energy earlier this month. “As America leads the global transition to a low-carbon economy, the continued development of new and advanced nuclear technologies along with support for currently operating nuclear power plants is an important component of our clean energy strategy,” a White House fact sheet developed for the summit states. Many environmentalists are also giving nuclear energy a second look, as they seek practical solutions to constrain carbon emissions.
Nuclear energy facilities provide 63 percent of America’s zero-carbon electricity. Globally, nuclear power plants provide one-third of all zero-carbon electricity. One of nuclear energy’s major advantages relative to other low-carbon energy sources is its unique ability to produce large-scale electricity around-the-clock in extreme weather conditions. Nuclear energy facilities don’t rely on the wind blowing, the sun shining, or just-in-time deliveries of fuel by truck, barge, rail or pipeline. In 2014, the U.S. nuclear energy industry’s average capacity factor—a common measure of efficiency and reliability—was 92 percent.
To view the multimedia release go to:
http://www.multivu.com/players/English/7694251-nuclear-energy-cop21-climate-goals/
The National Mining Association (NMA) called on policymakers to reject an ill-conceived administration proposal that would jeopardize America’s electric grid and threaten the economic well-being of consumers and businesses. Recently, the Environmental Protection Agency’s (EPA) proposed aggressive guidelines for regulating greenhouse gas emissions from existing coal-based power plants that generate 40 percent of the nation’s electricity and which will raise the cost of electricity for all Americans, according to NMA.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221751-national-mining-association-affordable-reliable-electricity/
Today, the Television Bureau of Advertising (TVB), the not-for-profit trade association of America’s commercial broadcast television industry, the National Highway Traffic Safety Administration (NHTSA), and the Ad Council launched their 11th year of “Project Roadblock: Local TV Puts the Brakes on Drunk Driving.” Launched in December 2003, Project Roadblock is the local broadcast television industry’s extension of NHTSA and the Ad Council’s ‘Buzzed Driving is Drunk Driving’ PSA campaign. Since then, the multi-media campaign has served as an opportunity for local television stations to combat drunk driving by donating on-air, online and mobile advertising time and space for the PSAs. To date, broadcast TV stations across the nation have donated more than $34 million in media to support this effort.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391951-ad-council-tvb-nhtsa-partner-to-prevent-drunk-driving-fatalities-during-holidays/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
The Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) today announced its first-ever, national advertising campaign aimed at parents of children ages 8-14 to make sure their kids are consistently and properly wearing their seat belt every time the car is moving.
“Buckling up is an important habit to instill in children at a young age. As parents, we need to lead by example and reinforce the message to make sure it sticks,” said U.S. Transportation Secretary Anthony Foxx. “This campaign urges parents to never give up until their kids buckle up.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7467951-psa-kids-seat-belt-safety-ad-council/
New proposed regulations from the Obama administration will force power plants to abandon the use of coal, the largest source of the nation’s electricity, resulting in higher utility bills for households and businesses and lost opportunities for responsibly reducing greenhouse gas emissions, the National Mining Association (NMA) said today.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63063-national-mining-association-nma-epa-new-source-performance-standard
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
